Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Oct 31, 2012 12:46pm
181 Views
Post# 20545124

RE: Brigus Gold closes $30-million Bought deal

RE: Brigus Gold closes $30-million Bought deal

RE:"Everyone knows it is a rip off but when you really need the cash and there is no viable alternative at that time ...

 

[S] Recall Apollo's financing at the dephs of the 2008 financial crisis. Thus BRD's streaming agreement, while NOT the most ideal arrangement, it should be compared to the deal with the Aussie bankers. In this environment lenders are very risk averse. Thus while a bot-deal has historically been positive news, the "market" continues to ignore BRD's increase in resources at Grey Fox.

 

The PEA is scheduled for release in November, historically a PEA was an automatic/synomous with a "re-rating" of the PPS.

 

BWDIK? In this market, lenders apperars to be risk averse.  Maybe after the US (re) election reality MAY return to the junior markets.

 

Cheers

Stanley

 

 

Bullboard Posts